» Articles » PMID: 32845392

Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences

Overview
Publisher Current Science
Specialty Rheumatology
Date 2020 Aug 27
PMID 32845392
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are auto-inflammatory and autoimmune diseases with a highly selective tissue tropism for medium and large arteries. In both diseases, CD4 T cells and macrophages form granulomatous lesions within the arterial wall, a tissue site normally protected by immune privilege. Vascular lesions can be accompanied by an extravascular component, typically an intense hepatic acute phase response that produces well-known laboratory abnormalities, e.g., elevated ESR and CRP. It is unclear whether GCA and TAK lie on a spectrum of disease or whether they represent fundamentally different disease processes.

Recent Findings: GCA and TAK share many clinical features, but there are substantial differences in genetics, epidemiology, disease mechanisms, response to treatment, and treatment complications that give rise to different disease trajectories. A significant difference lies in the composition of the wall-infiltrating immune cell compartment, which in TAK includes a significant population of CD8 T cells as well as natural killer cells, specifying disparate disease effector pathways mediating tissue damage and vessel wall remodeling. Despite the similarities in tissue tropism and histomorphology, GCA and TAK are two distinct vasculitides that rely on separate disease mechanisms and require disease-specific approaches in diagnosis and management.

Citing Articles

Single-cell transcriptome analysis reveals cellular heterogeneity in the aortas of Takayasu arteritis.

Gao N, Tang H, Li T, Yang Y, Zhao H, Wang L Arthritis Res Ther. 2025; 27(1):55.

PMID: 40065428 PMC: 11892157. DOI: 10.1186/s13075-025-03523-w.


Biologic therapies for the treatment of large vessel vasculitis: A systematic review and meta-analysis.

Chen S, Cui X, Chen Y, Guo X PLoS One. 2025; 20(3):e0314566.

PMID: 40063878 PMC: 11893120. DOI: 10.1371/journal.pone.0314566.


The Neutrophil to Lymphocyte Ratio and Other Full Blood Count Indices in Retinal Diseases: A Systematic Review of the Literature.

Kazantzis D, Machairoudia G, Theodossiadis P, Chatziralli I Medicina (Kaunas). 2025; 61(1.

PMID: 39859107 PMC: 11766500. DOI: 10.3390/medicina61010125.


mTOR signalling controls the formation of smooth muscle cell-derived luminal myofibroblasts during vasculitis.

Stock A, Parsons S, Hansen J, DSilva D, Starkey G, Fayed A EMBO Rep. 2024; 25(10):4570-4593.

PMID: 39271773 PMC: 11467406. DOI: 10.1038/s44319-024-00251-1.


Signal Regulatory Protein α Expression in Systemic Vasculitis.

Banerjee S, Rose E, Panicker S, Dugan J, Khalidi N, Koening C ACR Open Rheumatol. 2024; 6(10):634-640.

PMID: 39010674 PMC: 11471941. DOI: 10.1002/acr2.11716.


References
1.
Goldstein B, Gedmintas L, Todd D . Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol. 2014; 66(3):768-9. DOI: 10.1002/art.38282. View

2.
Weyand C, Goronzy J . Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014; 371(1):50-7. PMC: 4277693. DOI: 10.1056/NEJMcp1214825. View

3.
Pazzola G, Muratore F, Pipitone N, Crescentini F, Cacoub P, Boiardi L . Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). 2017; 57(7):1151-1155. DOI: 10.1093/rheumatology/kex249. View

4.
Akiyama M, Kaneko Y, Takeuchi T . Characteristics and prognosis of IgG4-related periaortitis/periarteritis: A systematic literature review. Autoimmun Rev. 2019; 18(9):102354. DOI: 10.1016/j.autrev.2019.102354. View

5.
Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View